Companies: 48,686 Total Market Cap: 130640275122363.03

BioNTech SE

NASDAQ: BNTX
Healthcare Biotechnology
Rank #899
Market Cap 23.21 B
Volume 257,531
Price 96.55
Change (%) 0.75%
Country or region Germany Germany

BioNTech SE's latest marketcap:

23.21 B

As of May 13, 2025, BioNTech SE's market capitalization has reached $23.21 B. According to our data, BioNTech SE is the 899th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 23.21 B
Revenue (ttm) 2.97 B
Net Income (ttm) -827,929,096
Shares Out 240.39 M
EPS (ttm) -3.45
Forward PE 0.00
Ex-Dividend Date n/a
Earnings Date May 5, 2025
Market Cap Chart
Data Updated: May 13, 2025

BioNTech SE's yearly market capitalization.

BioNTech SE has seen its market value grow from $19.63 B to $23.21 B since 2020, representing a total increase of 18.24% and an annual compound growth rate (CAGR) of 3.91%.
Date Market Cap Change (%)
May 13, 2025 $23.21 B -18.37%
December 31, 2024 $27.32 B 8.89%
December 29, 2023 $25.09 B -31.28%
December 30, 2022 $36.51 B -41.37%
December 31, 2021 $62.26 B 217.21%
December 31, 2020 $19.63 B

Company Profile

About BioNTech SE

BioNTech SE is a pioneering biotechnology company based in Mainz, Germany, specializing in the development and commercialization of immunotherapies for cancer and infectious diseases.

Key Product Pipeline

  • BNT111: Phase 2 clinical trial for advanced melanoma
  • BNT113: Phase 2 clinical trial for head and neck squamous cell carcinoma
  • BNT116: Phase 1 clinical trial for non-small cell lung cancer
  • BNT142: Phase 1/2 clinical trial for multiple solid tumors
  • BNT151: Phase 1/2 clinical trial for solid tumors
  • BNT152 + BNT153: Phase 1 clinical trial for solid tumors
  • BNT122/RO7198457: Phase 2 clinical trial for adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, and advanced melanoma

Additional Clinical Trials

  • BNT211: Phase 1 for CLDN6+ solid tumors
  • BNT221: Phase 1 for cancer treatment
  • BNT311/GEN1046 (acasunlimab): Phase 3 for solid tumors
  • BNT312/GEN1042: Phase 1/2 and 1 for solid tumors
  • BNT314/GEN1059: Phase 1/2 for advanced/metastatic solid tumors
  • BNT316/ONC-392: Phase 1/2, 2, and 3 for metastatic non-small cell lung cancer, platinum-resistant ovarian cancer, and other advanced tumors

Founded in 2008, BioNTech SE continues to lead innovation in immunotherapy, addressing some of the most challenging medical conditions worldwide.

Frequently Asked Questions

As of May 13, 2025, BioNTech SE (including the parent company, if applicable) has an estimated market capitalization of $23.21 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

BioNTech SE global market capitalization ranking is approximately 899 as of May 13, 2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region Germany
Founded 2008
IPO Date October 10, 2019
Employees 6,772
CEO Ugur Sahin
Sector Healthcare
Industry Biotechnology
Address An der Goldgrube 12
Mainz, 55131
Germany
People Also Watch
VRTX
439.66 0.75%
ASX-CSL
155.74 0.75%
REGN
567.37 0.75%
KRX-207940
705.60 0.75%